Originally published by our sister publication Clinical Oncology News
The FDA granted a new indication for olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm), metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.
Efficacy was evaluated in the PROpel trial that enrolled 796 patients with mCRPC. Patients were randomized in a